- NHL Treatment
- Hodgkin's Treatment
- Clinical Trials
- Monoclonal Antibodies
Hodgkin's lymphoma is a cancer of the lymphatic system. It affects the B-lymphocytes. Although first described in 1666, the disease gets its name from a Quaker physician named Thomas Hodgkin.
The National Cancer Institute's Surveillance Epidemiology and End Results statistics indicate that about 9,000 people will be diagnosed with Hodgkin's lymphoma this year in the United States. Slightly more of those diagnoses will be made in men than women. Furthermore, as many as 1,200 people are expected to die from the disease this year.
The primary difference between Hodgkin's disease and non-Hodgkin's lymphoma is what are called Reed-Sternberg cells, but these cells can only be found following a biopsy. More importantly, Hodgkin's lymphoma tends to make patients symptomatic and seek out a physician consult, leading to earlier detection of the disease and subsequently higher rates of cure than many other cancer types.
The median age at diagnosis for Hodgkin's lymphoma is 38 years.
The median age at death for Hodgkin's lymphoma is 64 years.
The 5-year relative survival rate of patients with Hodgkin's lymphoma in terms of when the disease is found and when treatment begins are as follows.
As is made very clear from these rates, Hodgkin's lymphoma is a highly treatable and often curable cancer.
The most commonly reported symptoms of Hodgkin's include the following: